Press

MindMed Reports Second Quarter 2022 Financial Results and Business Highlights

Aug 11 • 8 min read

Mind Medicine Inc. (NASDAQ: MNMD | NEO: MMED), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today reported its financial results for the quarter ended June 30, 2022. “In the second quarter, we took important steps to advance our ongoing development programs, which was highlighted by the progression of our Phase 2b dose-optimization trial of…

MindMed Co-Founder Dr. Scott Freeman Proposes Value Enhancement Plan

Aug 11 • 2 min read

Today, FCM MM HOLDINGS, LLC announced that it has sent a letter to the Board of Directors of Mind Medicine Inc. (NASDAQ: MNMD) calling on the Board to adopt a new strategic plan proposed by FCM including: refocusing on its core drugs, cutting cash burn, and terminating MindMed’s at-the-money equity offering. FCM is directed and…

PsyBio Therapeutics Strengthens IP Portfolio through Filing of Data to Support Previously Submitted Provisional Biosynthetic Production Patent Application

Aug 11 • 2 min read

PsyBio Therapeutics Corp. (TSXV: PSYB | OTCQB: PSYBF), an intellectual property driven biotechnology company focused upon discovery and development of novel, psycho-targeted therapeutics to potentially improve mental and neurological health, today is announcing the filing of data to support the conversion of a previously submitted provisional patent covering the biosynthetic production of methylated tryptamine derivatives including N,N-dimethyltryptamine and…

Lobe Sciences Enters into an Exclusive Agreement With iNGENu to Conduct Clinical Trials in Australia

Aug 11 • 2 min read

Lobe Sciences Ltd. (CSE: LOBE | OTCQB: LOBEF), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has entered into an exclusive agreement with iNGENū Pty Ltd., an Australian based Contract Research Organization (CRO), to design and conduct three or more clinical trials evaluating…

Optimi Health Unveils Canada’s First Natural Therapeutic Psilocybin Product For Approved Patients

Aug 10 • 4 min read

Optimi Health Corp. (CSE: OPTI | OTCQX: OPTHF | FRA: 8BN), a Canadian-based company licensed by Health Canada to produce natural, scalable, and accessible psychedelic and functional mushrooms, as well as synthetic formulations for transformational human experiences, is celebrating the launch of Blue Serenity, Canada’s first natural therapeutic psilocybin product, in collaboration with psilocybin patient advocate Thomas Hartle. Blue…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435